drugset / Trial / NCT05201469
VIBRANT: VIB4920 for Active Lupus Nephritis
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
Timeline
- Start
- 2022-12-15
- Primary completion
- 2028-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dazodalibep | Protein / enzyme biologic | 1500 mg | Intravenous |